Sugi Predict

Sugi Predict / Compounds / SCHEMBL4484994

SCHEMBL4484994

SCHEMBL4484994

CC(c1ccc(Cl)c(Cl)c1)N1CCO[C@@H](CNC(=O)NCc2nnn(C)n2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 4/20 0.45
▸ KCNH2 Q12809 4/20 0.40
▸ CCR2 P41597 1/20 0.40
▸ HRH1 P35367 2/20 0.35
▸ EPHA2 P29317 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ EPHB4 P54760 2/20 0.35
▸ OGA O60502 1/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ KCNK3 O14649 1/20 0.34
▸ ACKR3 P25106 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ ERBB2 P04626 1/20 0.34
▸ CACNA1H O95180 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ ADRA2A P08913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481315 0.88 MAPK1 (0.38) CCR3OGAMAPK1KCNK3ACKR3
SCHEMBL2344050 0.82 CCR3 (0.67) CCR3KCNH2CCR2CACNA1HMEN1
SCHEMBL4482563 0.82 CCR3 (0.67) CCR3KCNH2CCR2CACNA1HMEN1
SCHEMBL13631405 0.82 CCR3 (0.42) CCR3KCNH2CCR2HRH1EPHA2
SCHEMBL4474929 0.81 CCR2 (0.48) CCR3KCNH2CCR2HRH1EPHA2
SCHEMBL7104200 0.81 CCR3 (0.70) CCR3KCNH2CCR2HRH1OGA
SCHEMBL5619221 0.81 CCR3 (0.70) CCR3KCNH2CCR2HRH1OGA
SCHEMBL4478628 0.78 CCR3 (0.45) CCR3KCNH2CCR2HRH1EPHA2
SCHEMBL4487130 0.76 CCR3 (0.63) CCR3KCNH2CCR2HRH3CACNA1H
SCHEMBL4737944 0.76 CCR3 (0.63) CCR3KCNH2CCR2HRH3CACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 — — US disclosed
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 — — US disclosed
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 — — US disclosed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 — — EP disclosed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 — — EP disclosed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063765-A1 Novel compounds CCR3, NSUN3, CCR1 CCR3 1/4885KCNH2 2405/4885CCR2 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.